Based on the quantified dot blot data of 87 colorectal cancer patients and 42 healthy controls, an ROC curve of detected anti-FIRs antibodies and three clinically used tumor markers (anti-p53 antibody, CEA, and CA19-9) was examined (Figure 3C). This evidence concerns the gene TP53 and colorectal cancer.